From Botox to senolytics: Rubedo's AI-driven quest to make ageing a treatable condition

Key points

Key takeaways from a theCUBE + NYSE Wired: NYSE RX interview with Frederick Beddingfield, CEO of Rubedo Life Sciences (October 2026):

Science over snake oil. Beddingfield says most of the longevity space is noise without good data; Rubedo develops new chemical entities recognised by the FDA as drugs, using AI-enabled drug discovery, single-cell RNA sequencing and genomics.

Phase 2 lead asset. RLS-1496, a GPX4 modulator targeting dysfunctional senescent cells, is in Phase 2 with human proof of concept on efficacy and safety — one of very few drugs in ageing science to reach that point.

Skin first, body next. A topical form (cream, foam or oil) is in trials, from 16 months of clinical development to Phase 2a/2b; an oral version for metabolic and neurological diseases is about a year from human trials. The topical itself could be a blockbuster.

AI leapfrog. Rubedo was last into GPX4 among roughly eight companies studying the target, but AI-accelerated discovery — plus the topical-first route — let it leapfrog rivals including AbbVie, Takeda and Bayer into the clinic first.

The ALEMBIC platform. A proprietary database of over 150 million human cells, each evaluated at multiomic level (single-cell RNA, spatial transcriptomics, genomics, epigenetics, proteomics), lets AI find what differs between healthy and diseased or aged cells.

Senolysis with a twist. The drug clears senescent cells yet also revitalises ageing but not-yet-senescent cells — "what doesn't kill you makes you stronger" — with Columbia-published stem-cell mechanisms behind promising hair-regeneration data.

Hair loss opportunity. Actinic keratosis showed strong Phase 2a data; the first human trial in androgenetic alopecia (male pattern baldness) starts imminently, in a market where no novel drug has been approved in decades and minoxidil/finasteride remain the standard of care.

Fundraising. Having raised over $90m to date (Series B), Rubedo has kicked off a Series C to fund Phase 3 in hair loss and Phase 2b in actinic keratosis, with strategic-pharma partnerships welcome but rights not given away early.

Read more: theCUBE on YouTube